The support of human genetic evidence for approved drug indications

Matthew R. Nelson, Hannah Tipney, Jeffery L. Painter, Judong Shen, Paola Nicoletti, Yufeng Shen, Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, Lon R. Cardon, John C. Whittaker, Philippe Sanseau

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

Over a quarter of drugs that enter clinical development fail because they are ineffective. Growing insight into genes that influence human disease may affect how drug targets and indications are selected. However, there is little guidance about how much weight should be given to genetic evidence in making these key decisions. To answer this question, we investigated how well the current archive of genetic evidence predicts drug mechanisms. We found that, among well-studied indications, the proportion of drug mechanisms with direct genetic support increases significantly across the drug development pipeline, from 2.0% at the preclinical stage to 8.2% among mechanisms for approved drugs, and varies dramatically among disease areas. We estimate that selecting genetically supported targets could double the success rate in clinical development. Therefore, using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.

Original languageEnglish (US)
Pages (from-to)856-860
Number of pages5
JournalNature Genetics
Volume47
Issue number8
DOIs
StatePublished - Aug 30 2015
Externally publishedYes

Fingerprint

Medical Genetics
Pharmaceutical Preparations
Decision Making
Weights and Measures
Genes

ASJC Scopus subject areas

  • Genetics
  • Medicine(all)

Cite this

Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., ... Sanseau, P. (2015). The support of human genetic evidence for approved drug indications. Nature Genetics, 47(8), 856-860. https://doi.org/10.1038/ng.3314

The support of human genetic evidence for approved drug indications. / Nelson, Matthew R.; Tipney, Hannah; Painter, Jeffery L.; Shen, Judong; Nicoletti, Paola; Shen, Yufeng; Floratos, Aris; Sham, Pak Chung; Li, Mulin Jun; Wang, Junwen; Cardon, Lon R.; Whittaker, John C.; Sanseau, Philippe.

In: Nature Genetics, Vol. 47, No. 8, 30.08.2015, p. 856-860.

Research output: Contribution to journalArticle

Nelson, MR, Tipney, H, Painter, JL, Shen, J, Nicoletti, P, Shen, Y, Floratos, A, Sham, PC, Li, MJ, Wang, J, Cardon, LR, Whittaker, JC & Sanseau, P 2015, 'The support of human genetic evidence for approved drug indications', Nature Genetics, vol. 47, no. 8, pp. 856-860. https://doi.org/10.1038/ng.3314
Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y et al. The support of human genetic evidence for approved drug indications. Nature Genetics. 2015 Aug 30;47(8):856-860. https://doi.org/10.1038/ng.3314
Nelson, Matthew R. ; Tipney, Hannah ; Painter, Jeffery L. ; Shen, Judong ; Nicoletti, Paola ; Shen, Yufeng ; Floratos, Aris ; Sham, Pak Chung ; Li, Mulin Jun ; Wang, Junwen ; Cardon, Lon R. ; Whittaker, John C. ; Sanseau, Philippe. / The support of human genetic evidence for approved drug indications. In: Nature Genetics. 2015 ; Vol. 47, No. 8. pp. 856-860.
@article{9d04d92f0bf64ee48940c73009fbe2be,
title = "The support of human genetic evidence for approved drug indications",
abstract = "Over a quarter of drugs that enter clinical development fail because they are ineffective. Growing insight into genes that influence human disease may affect how drug targets and indications are selected. However, there is little guidance about how much weight should be given to genetic evidence in making these key decisions. To answer this question, we investigated how well the current archive of genetic evidence predicts drug mechanisms. We found that, among well-studied indications, the proportion of drug mechanisms with direct genetic support increases significantly across the drug development pipeline, from 2.0{\%} at the preclinical stage to 8.2{\%} among mechanisms for approved drugs, and varies dramatically among disease areas. We estimate that selecting genetically supported targets could double the success rate in clinical development. Therefore, using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.",
author = "Nelson, {Matthew R.} and Hannah Tipney and Painter, {Jeffery L.} and Judong Shen and Paola Nicoletti and Yufeng Shen and Aris Floratos and Sham, {Pak Chung} and Li, {Mulin Jun} and Junwen Wang and Cardon, {Lon R.} and Whittaker, {John C.} and Philippe Sanseau",
year = "2015",
month = "8",
day = "30",
doi = "10.1038/ng.3314",
language = "English (US)",
volume = "47",
pages = "856--860",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - The support of human genetic evidence for approved drug indications

AU - Nelson, Matthew R.

AU - Tipney, Hannah

AU - Painter, Jeffery L.

AU - Shen, Judong

AU - Nicoletti, Paola

AU - Shen, Yufeng

AU - Floratos, Aris

AU - Sham, Pak Chung

AU - Li, Mulin Jun

AU - Wang, Junwen

AU - Cardon, Lon R.

AU - Whittaker, John C.

AU - Sanseau, Philippe

PY - 2015/8/30

Y1 - 2015/8/30

N2 - Over a quarter of drugs that enter clinical development fail because they are ineffective. Growing insight into genes that influence human disease may affect how drug targets and indications are selected. However, there is little guidance about how much weight should be given to genetic evidence in making these key decisions. To answer this question, we investigated how well the current archive of genetic evidence predicts drug mechanisms. We found that, among well-studied indications, the proportion of drug mechanisms with direct genetic support increases significantly across the drug development pipeline, from 2.0% at the preclinical stage to 8.2% among mechanisms for approved drugs, and varies dramatically among disease areas. We estimate that selecting genetically supported targets could double the success rate in clinical development. Therefore, using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.

AB - Over a quarter of drugs that enter clinical development fail because they are ineffective. Growing insight into genes that influence human disease may affect how drug targets and indications are selected. However, there is little guidance about how much weight should be given to genetic evidence in making these key decisions. To answer this question, we investigated how well the current archive of genetic evidence predicts drug mechanisms. We found that, among well-studied indications, the proportion of drug mechanisms with direct genetic support increases significantly across the drug development pipeline, from 2.0% at the preclinical stage to 8.2% among mechanisms for approved drugs, and varies dramatically among disease areas. We estimate that selecting genetically supported targets could double the success rate in clinical development. Therefore, using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.

UR - http://www.scopus.com/inward/record.url?scp=84938292742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938292742&partnerID=8YFLogxK

U2 - 10.1038/ng.3314

DO - 10.1038/ng.3314

M3 - Article

C2 - 26121088

AN - SCOPUS:84938292742

VL - 47

SP - 856

EP - 860

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 8

ER -